Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gil Ma is active.

Publication


Featured researches published by Gil Ma.


Journal of Organic Chemistry | 2011

Bioinspired total synthesis and human proteasome inhibitory activity of (-)-salinosporamide A, (-)-homosalinosporamide A, and derivatives obtained via organonucleophile promoted bis-cyclizations.

Henry Nguyen; Gil Ma; Tatiana Gladysheva; Trisha Fremgen; Daniel Romo

A full account of concise, enantioselective syntheses of the anticancer agent (-)-salinosporamide A and derivatives, including (-)-homosalinosporamide, that was inspired by biosynthetic considerations is described. The brevity of the synthetic strategy stems from a key bis-cyclization of a β-keto tertiary amide, which retains optical purity enabled by A(1,3)-strain rendering slow epimerization relative to the rate of bis-cyclization. Optimization studies of the key bis-cyclization, enabled through byproduct isolation and characterization, are described that ultimately allowed for a gram scale synthesis of a versatile bicyclic core structure with a high degree of stereoretention. An optimized procedure for zincate generation by the method of Knochel, generally useful for the synthesis of salino A derivatives, led to dramatic improvements in side-chain attachment and a novel diastereomer of salino A. The versatility of the described strategy is demonstrated by the synthesis of designed derivatives including (-)-homosalinosporamide A. Inhibition of the human 20S and 26S proteasome by these derivatives using an enzymatic assay are also reported. The described total synthesis of salino A raises interesting questions regarding how biosynthetic enzymes leading to the salinosporamides proceeding via optically active β-keto secondary amides, are able to maintain the stereochemical integrity at the labile C2 stereocenter or if a dynamic kinetic resolution is operative.


Chemical Communications | 2010

A1,3-strain enabled retention of chirality during bis-cyclization of β-ketoamides: total synthesis of (−)-salinosporamide A and (−)-homosalinosporamide A

Henry Nguyen; Gil Ma; Daniel Romo

A concise, enantioselective synthesis of the Phase I anticancer agent, (-)-salinosporamide A, is described. The brevity of the described strategy stems from a key bis-cyclization of a beta-keto tertiary amide, accomplished on gram scale, which retains optical purity enabled by A(1,3)-strain rendering epimerization slow relative to the rate of bis-cyclization. The versatility of the strategy for derivative synthesis is demonstrated by the synthesis of (-)-homosalinosporamide A.


Journal of Medicinal Chemistry | 2008

Synthesis of Novel β-Lactone Inhibitors of Fatty Acid Synthase

Robyn D. Richardson; Gil Ma; Yatsandra Oyola; Manuel Zancanella; Lynn M. Knowles; Piotr Cieplak; Daniel Romo; Jeffrey W. Smith

Fatty acid synthase (FAS) is necessary for growth and survival of tumor cells and is a promising drug target for oncology. Here, we report on the syntheses and activity of novel inhibitors of the thioesterase domain of FAS. Using the structure of orlistat as a starting point, which contains a beta-lactone as the central pharmacophore, 28 novel congeners were synthesized and examined. Structural features such as the length of the alpha- and beta-alkyl chains, their chemical composition, and amino ester substitutions were altered and the resulting compounds explored for inhibitory activity toward the thioesterase domain of FAS. Nineteen congeners show improved potency for FAS in biochemical assays relative to orlistat. Three of that subset, including the natural product valilactone, also display an increased potency in inducing tumor cell death and improved solubility compared to orlistat. These findings support the idea that an orlistat congener can be optimized for use in a preclinical drug design and for clinical drug development.


Methods in Enzymology | 2007

Isolation and Identification of Eukaryotic Initiation Factor 4A as a Molecular Target for the Marine Natural Product Pateamine A

Woon Kai Low; Yongjun Dang; Tilman Schneider-Poetsch; Zonggao Shi; Nam Song Choi; Robert M. Rzasa; Helene A. Shea; Shukun Li; Kaapjoo Park; Gil Ma; Daniel Romo; Jun O. Liu

Natural products continue to demonstrate their utility both as therapeutics and as molecular probes for the discovery and mechanistic deconvolution of various cellular processes. However, this utility is dampened by the inherent difficulties involved in isolating and characterizing new bioactive natural products, in obtaining sufficient quantities of purified compound for further biological studies, and in developing bioactive probes. Key to characterizing the biological activity of natural products is the identification of the molecular target(s) within the cell. The marine sponge-derived natural product Pateamine A (PatA) has been found to be an inhibitor of eukaryotic translation initiation. Herein, we describe the methods utilized for identification of the eukaryotic translation initiation factor 4A (eIF4A) as one of the primary protein targets of PatA. We begin by describing the synthesis of an active biotin conjugate of PatA (B-PatA), made possible by total synthesis, followed by its use for affinity purification of PatA binding proteins from cellular lysates. We have attempted to present the methodology as a general technique for the identification of protein targets for small molecules including natural products.


Journal of Medicinal Chemistry | 2011

Tricyclic Thiazolopyrazole Derivatives as Metabotropic Glutamate Receptor 4 Positive Allosteric Modulators

Sang-Phyo Hong; Kevin G. Liu; Gil Ma; Michael Sabio; Michelle A. Uberti; Maria D. Bacolod; John R. Peterson; Zack Zou; Albert Jean Robichaud; Dario Doller

There is an increasing amount of evidence to support that activation of the metabotropic glutamate receptor 4 (mGlu4 receptor), either with an orthosteric agonist or a positive allosteric modulator (PAM), provides impactful interventions in diseases such as Parkinsons disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts in identifying therapeutics for central nervous system (CNS) diseases such as Parkinsons disease, we have been focusing on metabotropic glutamate receptors. Herein we report our studies with a series of tricyclic thiazolopyrazoles as mGlu4 PAMs.


Organic Letters | 2007

Concise Total Synthesis of (±)-Salinosporamide A, (±)-Cinnabaramide A, and Derivatives via a Bis-cyclization Process: Implications for a Biosynthetic Pathway?

Gil Ma; Henry Nguyen; Daniel Romo


Organic Letters | 2006

Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase.

Gil Ma; Manuel Zancanella; Yatsandra Oyola; Robyn D. Richardson; Jeffrey W. Smith; Daniel Romo


Archive | 2008

BETA-LACTONE COMPOUNDS

Jeffrey W. Smith; Daniel Romo; Gil Ma; Manuel Zancanella


Archive | 2017

composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.

Andrew D. White; Dario Doller; Gil Ma; Guiying Li; Hermogenes N. Jimenez; Maojun Guo; Michel Grenon


Archive | 2009

Dérivés de l'indole

Yu Jiang; Sang-phyo Hong; Bin Chen; Eman Mohamed Eldemenky; Arifa Husain; Lingyun Wu; Kai Lu; Gil Ma; Marc Labelle; Mohammad R. Marzabadi; Michael Sabio; Andrew D. White; Christine Mazza; Mathivanan Packiarajan

Collaboration


Dive into the Gil Ma's collaboration.

Researchain Logo
Decentralizing Knowledge